Jason Coloma, Maze Therapeutics CEO

Up­dat­ed: Maze re­veals pos­i­tive first look at PhI Pompe dis­ease can­di­date

The sci­en­tists at Maze Ther­a­peu­tics call them­selves “ge­net­ic nav­i­ga­tors,” and on Thurs­day, they mapped out some pos­i­tive Phase I re­sults from their most ad­vanced pro­gram …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.